Linezolid Use With Concomitant Serotonergic Agents

SIDP Reviewers

This article was reviewed by Society of Infectious Diseases Pharmacists committee members Mandee Booth, PharmD, BCIDP; and Alyssa Christensen, PharmD, BCIDP.

Background

Linezolid (Zyvox; Pfizer) is an oxazolidinone antimicrobial used for the treatment of a variety of infectious diseases caused by gram-positive bacteria—including skin and soft tissue infections, pneumonia, and bacteremia—in addition to less common syndromes such as multidrug-resistant tuberculosis.¹ Although linezolid is highly effective and versatile, it does come with several adverse effects (AEs), one of which is serotonin syndrome.

First described in 1962,² serotonin syndrome is a rare adverse drug reaction with symptoms that typically onset within 24 hours and range from mild to potentially life-threatening (Table).³ Management involves the prompt removal of the precipitating drugs and supportive care. Although resolution of the syndrome typically occurs within 24 hours of discontinuing the offending drug, symptoms may persist depending on the half-lives and the presence of active metabolites of the offending agent.

While the FDA noted this potential concern with its original approval, it strengthened the warning in 2011 surrounding the use of linezolid with concomitant serotonergic agents after postmarketing reports of serotonin syndrome.⁴

Mechanism of Interaction, Incidence, and Risks

The serotonin signaling pathway is a multistep process that involves the following: the synthesis of serotonin from tryptophan; the release of serotonin from presynaptic vesicles into the synaptic cleft; the reuptake of free serotonin in the synaptic cleft by serotonin transporter; and the metabolism of serotonin into inactive metabolites by monoamine oxidase (MAO).³ Linezolid is thought to contribute to the risk of serotonin syndrome due to its weak inhibition of MAO enzymes. When used in the presence of an MAO inhibitor, the additive inhibition of serotonin metabolism may pose an increased risk for serotonin syndrome. When used in combination with a serotonergic agent such as a selective serotonin reuptake inhibitor (SSRI) or a serotonin and norepinephrine reuptake inhibitor (SNRI), decreased serotonin reuptake into the presynaptic neuron results in higher synaptic serotonin levels, thereby increasing the risk of serotonin syndrome.⁴ Although the incidence of serotonin syndrome is relatively low, the package insert recommends avoiding the concurrent use of linezolid with any MAO enzyme inhibitors. It suggests discontinuing other serotonergic agents, such as SSRIs or SNRIs.¹ While data from various studies support a potential increased risk of serotonin syndrome,^5,6 modern comparisons suggest the incidence of this complication is rare, with less than 1% of patients, including those taking multiple concomitant SSRIs/SNRIs.^7-9

Importantly, the risk may be highest with agents that have specific pharmacokinetic and pharmacodynamic properties, such as higher binding affinity for the serotonin reuptake transporter or greater lipophilicity, resulting in greater penetration into the central nervous system.¹⁰ Examples of these medications include methadone (Dolophine, Methadose; Roxane Laboratories, Mallinckrodt Pharmaceuticals, respectively), escitalopram (Lexapro; Forest Laboratories), and citalopram (Celexa; Forest Laboratories), which may warrant additional caution when used with linezolid compared with other serotonergic medications.

Clinical Implication

Linezolid may often be unnecessarily avoided in patients on concomitant serotonergic agents. While the risk of linezolid-associated serotonin syndrome should be evaluated in all patients, it may be highest in patients prescribed specific medications such as citalopram, escitalopram, and methadone, where additional caution may be utilized. As the incidence of serotonin syndrome is rare, the combination may be considered with proper patient selection and counseling in the ambulatory setting to immediately stop linezolid if signs and symptoms of serotonin syndrome develop or with close monitoring in an inpatient setting. In these situations, the benefits can outweigh the risk of this reaction of linezolid if it is determined to be the most appropriate antibiotic. Lastly, linezolid should not be used with another MAOI unless a minimum 2-week MAO inhibitor washout period has been completed, given the lack of modern safety data demonstrating minimal risk of the additive inhibition of metabolism from linezolid in the presence of an MAO inhibitor.

Conclusion

Although linezolid carries a well-documented warning for serotonin syndrome, contemporary evidence suggests that this AE remains rare, even among patients receiving concomitant serotonergic therapy. Understanding the underlying pharmacologic mechanisms, recognizing higher-risk drug combinations, and taking patient-specific factors into consideration allow health care professionals to better contextualize this interaction rather than reflexively avoid an otherwise highly effective antimicrobial. With appropriate patient selection, counseling, and monitoring, linezolid can often be used safely when clinically indicated, preserving its important role in the management of serious gram-positive infections.

Ultimately, the decision to use linezolid alongside serotonergic agents should be guided by a balanced assessment of risks and benefits, infection severity, and available therapeutic alternatives. Pharmacists and prescribers play a central role in identifying high-risk combinations, educating patients about early symptoms, and ensuring close follow-up when therapy is initiated. Through individualized care and evidence-informed decision-making, clinicians can minimize preventable harm while ensuring patients receive timely and effective antimicrobial treatment.

REFERENCES

1. Zyvox. Prescribing information. Pfizer Inc; 2000. Accessed March 27, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021130s032,021131s026,021132s031lbl.pdf

2. Smith B, Prockop DJ. Central-nervous-system effects of ingestion of L-tryptophan by normal subjects. N Engl J Med. 1962;267(26):1338-1341. doi:10.1056/nejm196212272672603

3. Sahu A, Gopalakrishnan L, Gaur N, et al. The 5-hydroxytryptamine signaling map: an overview of serotonin–serotonin receptor mediated signaling network. J Cell Commun Signal. 2018;12(4):731-735. doi:10.1007/s12079-018-0482-2

4. Mikkelsen N, Damkier P, Pedersen SA. Serotonin syndrome - a focused review. Basic Clin Pharmacol Toxicol. 2023;133(2):124-129. doi:10.1111/bcpt.13912

5. FDA drug safety communication: serious CNS reactions possible when linezolid (Zyvox) is given to patients taking certain psychiatric medications. FDA. July 26, 2011. Updated December 14, 2017. Accessed December 17, 2025. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-serious-cns-reactions-possible-when-linezolid-zyvox-given-patients

6. Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. Clin Infect Dis. 2006;43(2):180-187. doi:10.1086/504809

7. Clark DB, Andrus MR, Byrd DC. Drug interactions between linezolid and selective serotonin reuptake inhibitors: case report involving sertraline and review of the literature. Pharmacotherapy. 2006;26(2):269-276. doi:10.1592/phco.26.2.269

8. Kufel WD, Parsels KA, Blaine BE, Steele JM, Seabury RW, Asiago-Reddy EA. Real-world evaluation of linezolid-associated serotonin toxicity with and without concurrent serotonergic agents. Int J Antimicrob Agents. 2023;62(1):106843. doi:10.1016/j.ijantimicag.2023.106843

9. Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise TP. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data. J Antimicrob Chemother. 2012;67(2):494-502. doi:10.1093/jac/dkr467

10. Gatti M, Raschi E, De Ponti F. Serotonin syndrome by drug interaction with linezolid: clues from pharmacovigilance–pharmacokinetic/pharmacodynamic analysis. Eur J Clin Pharmacol. 2021;77(2):233-239. doi:10.1007/s00228-020-02990-1